[1]
|
Parkin, D.M. (2005) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 55, 74-108.
https://doi.org/10.3322/canjclin.55.2.74
|
[2]
|
马玲玲. 头颈部鳞癌HPV感染与p16、EGFR表达的关系及预后关系的研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2013.
|
[3]
|
冯守昊, 嵇庆海, 王玉龙. 表皮生长因子受体靶向治疗在头颈部鳞癌中的研究现状[J]. 中国癌症杂志中国癌症杂志, 2012, 22(12): 934-941.
|
[4]
|
顾倩平, 孟箭, 孟庆飞, 张杰, 李志萍. 尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶治疗晚期口腔癌的短期疗效观察[J]. 国际口腔医学杂志, 2011, 38(6): 652-655.
|
[5]
|
刘芬. 基于炮制原理的麸炒苍术药效及作用机制研究[D]: [博士学位论文]. 武汉: 湖北中医药大学, 2018.
|
[6]
|
张丹丹, 姚立. 京尼平苷通过抑制EGFR/PI3K/AKT通路和Ca2+通道减轻CCI大鼠的神经性疼痛[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2023.
|
[7]
|
伦立鑫, 钟振滨, 赵新宇, 等. 抗EGFR治疗在头颈部鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 276-280.
|
[8]
|
Falls, D.L. (2003) Neuregulins: Functions, Forms, Signalings Strategies. Experimental Cell Research, 284, 14-30.
https://doi.org/10.1016/S0014-4827(02)00102-7
|
[9]
|
Bonner, J.A., Harari, P.M., Giralt, J., et al. (2006) Radio-therapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine, 354, 567-579. https://doi.org/10.1056/NEJMoa053422
|
[10]
|
Bonner, J.A., Harari, P.M., Giralt, J., et al. (2010) Ra-diotherapy plus Cetuximab for Locoregionally Advanced Head and Neck Cancer: 5-Year Survival Data from a Phase 3 Randomised Trial, and Relation between Cetuximab-Induced Rash and Survival. The Lancet Oncology, 11, 21-28. https://doi.org/10.1016/S1470-2045(09)70311-0
|
[11]
|
Burtness, B., Goldwasser, M.A., Flood, W., et al. (2005) Phase Ⅲ Randomized Trial of Cisplatin plus Placebo Compared with Cisplatin plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. Journal of Clinical Oncology, 23, 8646-8654. https://doi.org/10.1200/JCO.2005.02.4646
|
[12]
|
Vermorken, J.B., Mesia, R., Rivera, F., et al. (2008) Platinum Based Chemotherapy plus Cetuximab in Head and Neck Cancer. The New England Journal of Medicine, 359, 1116-1127. https://doi.org/10.1056/NEJMoa0802656
|
[13]
|
Pfister, D.G., Su, Y.B., Kraus, D.H., et al. (2006) Concurrent Etuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm. Journal of Clinical Oncology, 24, 1072-1078. https://doi.org/10.1200/JCO.2004.00.1792
|
[14]
|
Wirth, L.J., Allen, A.M., Posner, M.R., et al. (2010) Phase I Dosefinding Study of Paclitaxel with Panitumumab, Carboplatin and Ntensity-Modulated Radiotherapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Annals of Oncology, 21, 342-347. https://doi.org/10.1093/annonc/mdp477
|
[15]
|
Rischin, D., Spigel, D.R., Adkins, D., et al. (2010) Panitumumab (PMAB) Regimen in Second-Line Onotherapy (PRISM) in Patients (PTS) with Recurrent (R) or Metastatic (M) Squa-mous Cell Carcinoma of the Head and Neck (HNSCC): Interim Safety Analysis. Annals of Oncology, 21, Article 323.
|
[16]
|
Vermorken, J.B., Stohlmacher, J., Davidenko, I., et al. (2010) Primary Efficacy and Safety Results of SPECTRUM, a Phase 3 Trial in Patients (PTS) with Recurrent and/or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) Receiving Chemotherapy with or without Panitumumab (PMAB). Annals of Oncology, 21, Article LBA26.
|
[17]
|
王亚琛, 郑旸, 杨月美, 等. 尼妥珠单抗与TPF的联合运用在头颈鳞癌中治疗效果的初步分析[J]. 口腔医学, 2023, 43(4): 312-316.
|
[18]
|
Rodríguez, M.O., Rivero, T.C., Del-Castillo, B.R., et al. (2010) Nimotuzumab plus Radiotherapy for Unresectable Squamous-Cell Carcinoma of the Head and Neck. Cancer Biology & Therapy, 9, 343-349.
https://doi.org/10.4161/cbt.9.5.10981
|
[19]
|
王红, 吴云腾, 马旭辉, 等. EGFR单抗联合化疗治疗245例晚期头颈鳞癌疗效分析[J]. 中国口腔颌面外科杂志, 2019, 17(2): 129-133.
|
[20]
|
郭伟, 孙沫逸, 冉炜, 等. 尼妥珠单克隆抗体注射液治疗口腔颌面-头颈部鳞癌专家共识[J]. 实用口腔医学杂志, 2021, 37(4): 445-450.
|
[21]
|
Cohen, E.E.W., Rosen, F., Stadler, W.M., et al. (2003) Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 21, 1980-1987.
https://doi.org/10.1200/JCO.2003.10.051
|
[22]
|
Cohen, E.E.W., Kane, M.A., List, M.A., et al. (2005) Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 11, 8418-8424.
https://doi.org/10.1158/1078-0432.CCR-05-1247
|
[23]
|
Hainsworth, J.D., Spigel, D.R., Burris, H.A., et al. (2009) Neoadjuvant Chemotherapy/Gefitinib Followed by Concurrent Chemotherapy/Radiation Therapy/Gefitinib for Patients with Locally Advanced Squamous Carcinoma of the Head and Neck. Cancer, 115, 2138-2146. https://doi.org/10.1002/cncr.24265
|
[24]
|
Siu, L.L., Soulieres, D., Chen, E.X., et al. (2007) Phase I/II Trial of Erlo-tinib and Cisplatin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology, 25, 2178-2183.
https://doi.org/10.1200/JCO.2006.07.6547
|
[25]
|
Herchenhorn, D., Dias, F.L., Viegas, C.M., et al. (2010) Phase I/II Study of Erlotinib Combined with Cisplatin and Radiotherapy in Patients with Locally Advanced Squamous Cell Carci-noma of the Head and Neck. International Journal of Radiation Oncology, Biology, Physics, 78, 696-702. https://doi.org/10.1016/j.ijrobp.2009.08.079
|
[26]
|
Kao, J., Genden, E.M., Chen, C.T., et al. (2011) Phase 1 Trial of Concurrent Erlotinib, Celecoxib, and Reirradiation for Recurrent Head and Neck Cancer. Cancer, 117, 3173- 3181. https://doi.org/10.1002/cncr.25786
|
[27]
|
Gilbert, J., Rudek, M.A., Higgins, M.J., et al. (2012) A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 18, 1735-1742.
https://doi.org/10.1158/1078-0432.CCR-11-2544
|
[28]
|
Verma, J., Dhingra, V., Srivastava, S., et al. (2018) Evalua-tion of Epidermal Growth Factor Receptor Expression by a New Scoring System in Head-and-Neck Squamous Cell Car-cinoma and Its Association with Various Pathological Prognostic Factors. Journal of Oral and Maxillofacial Pathology, 22, 11-17.
https://doi.org/10.4103/jomfp.JOMFP_137_16
|
[29]
|
陈晓钟, 金祁峰. 免疫检查点抑制剂在头颈部鳞癌治疗中的应用研究进展[J]. 浙江医学, 2023, 45(10): 1009-1012, 1018.
|
[30]
|
Napolitano, S., Matrone, N., Muddassir, A.L., Martini, G., Sorokin, A., De Falco, V., Giunta, E.F., Ciardiello, D., Martinelli, E., Belli, V., Furia, M., Kopetz, S., Mor-gillo, F., Ciardiello, F. and Troiani, T. (2019) Triple Blockade of EGFR, MEK and PD-L1 Has Antitumor Activity in Colorectal Cancer Models with Constitutive Activation of MAPK Signaling and PD-L1 Overexpression. Journal of Ex-perimental & Clinical Cancer Research, 38, Article No. 492.
https://doi.org/10.1186/s13046-019-1497-0
|
[31]
|
Zhang, J., Dang, F., Ren, J. and Wei, W. (2018) Biochemical As-pects of PD-L1 Regulation in Cancer Immunotherapy. Trends in Biochemical Sciences, 43, 1014-1032. https://doi.org/10.1016/j.tibs.2018.09.004
|